Sample size feasible [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2012-02-08 10:47 (4826 d 02:17 ago) – Posting: # 8071
Views: 21,439

Dear AB,

if your point estimator is ok (i.e. in the range 0.95 ... 1.0526) a sample size estimation with your ISCV and a full replicate design (2-sequence-4-period) gives (using R with package PowerTOST)
library(PowerTOST)
sampleN.TOST(CV=0.47, design="2x2x4")

+++++++++++ Equivalence test - TOST +++++++++++
            Sample size estimation
-----------------------------------------------
Study design:  2x2x4 replicate crossover
log-transformed data (multiplicative model)

alpha = 0.05, target power = 0.8
BE margins        = 0.8 ... 1.25
Null (true) ratio = 0.95,  CV = 0.47

Sample size (total)
 n     power
44   0.806110


Thus the chance with a feasible sample size is greater then anticipated by my previous speaker above :cool:.

But the question remains: Why do you resist in using the 80-125% acceptance range also the EMA allows you a widening :confused:. Or is your ISCV from AUC?

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
20 visitors (0 registered, 20 guests [including 2 identified bots]).
Forum time: 14:05 CEST (Europe/Vienna)

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5